BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest Therapeutics (TPST)Tempest TherapeuticsPartnership

Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications Senlang Biotechnology, a

Related news

TPSTTempest Therapeutics2026-09-15 20:05 EST

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

REGNRegeneron Pharmaceuticals2026-10-01 05:00 EST

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

TPSTTempest Therapeutics2026-09-23 12:00 EST

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

LEGNLegend Biotech Corporation2026-10-01 13:00 EST

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

IDYAIDEAYA Biosciences2026-09-28 10:00 EST

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-09-23 12:00 EST

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

TPSTTempest Therapeutics2026-09-15 20:05 EST

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

TPSTTempest Therapeutics2026-09-08 12:30 EST

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TPSTTempest Therapeutics2026-08-13 20:26 EST

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
0.81 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States